Introduction
The p53 protein plays a crucial role as a tumor suppressor. Depending on the exact cellular context, p53 acts by causing cells to undergo either cell cycle arrest or apoptosis in response to cellular stresses (Bargonetti and Manfredi, 2002) . In some cell types, gamma-irradiation induces a p53-dependent G1 arrest checkpoint response that is proposed to prevent the propagation of oncogenic mutations by blocking the progression of cells through the cycle (Kastan et al., 1992; Wahl and Carr, 2001) . In other situations, p53 responds to stresses including DNA damage, hyperproliferation, or hypoxia by causing cells to undergo apoptosis (Lowe et al., 1993; Soengas et al., 1999) , thus efficiently eliminating aberrantly proliferating cells or cells with damaged genomes, either of which could be dangerous for an organism. It is not well understood what dictates whether cells arrest or undergo apoptosis in response to stress, but it seems to be related to cell type, specific stress, and cellular milieu.
Primary mouse embryo fibroblasts (MEFs) provide an ideal model system for studying both the G1 arrest and the apoptotic functions of p53. Wild-type MEFs undergo G1 arrest when treated with gamma-irradiation, while p53-null MEFs fail to do so (Kastan et al., 1992) . Oncogene expression in MEFs, which renders cells neoplastic, reprograms fibroblasts that are exposed to cellular stresses to undergo apoptosis, providing a model system for p53-dependent apoptosis (Lowe et al., 1993) . In particular, MEFs expressing adenovirus E1A and activated ras undergo p53-dependent apoptosis when treated with DNAdamaging or chemotherapeutic agents such as gammarays, doxorubicin, etoposide, and cisplatin. This p53-dependent apoptotic pathway is important for the response of mouse tumors to chemotherapy (Johnstone et al., 2002) .
Studying normal and neoplastic MEFs thus has great significance for understanding the mode of action of cancer therapies. As anticancer agents are rarely selective for tumor cells, it is important to define their effects on both normal and neoplastic cells. Although the G1 arrest response of MEFs to gammairradiation has been well characterized, the response to other DNA-damaging agents has not been thoroughly examined. Here, we characterize the effects of several commonly utilized chemotherapeutic agents, as well as ultraviolet light (UVC), in the p53-dependent G1 arrest response of MEFs. We find that different DNAdamaging agents, despite having the common effect of inducing p53, have different activities in cell cycle arrest in MEFs.
Results

Various DNA-damaging agents induce apoptosis in E1A-expressing MEFs
Oncogenic signals are required to sensitize MEFs to apoptosis by most DNA-damaging agents. For example, MEFs treated with gamma-irradiation, doxorubicin, or etoposide do not undergo apoptosis (Lowe et al., 1993) . In contrast, MEFs coexpressing the adenovirus E1A and ras oncoproteins and treated with DNA-damaging or chemotherapeutic agents undergo p53-dependent apoptosis, instead of cell cycle arrest. We tested the response of E1A-expressing MEFs to several of the agents we planned to analyse for activity in cell cycle arrest in MEFs to define the efficacy of apoptosis induction by p53. We characterized the apoptotic response of E1A-MEFs to doxorubicin, etoposide, and cisplatin, 48 h after treatment, using doses that had been previously reported to induce apoptosis in E1A, ras-expressing MEFs (Lowe et al., 1993, JS Lanni, personal communication) . In a representative experiment, 0.2 mg/ml doxorubicin, 2 mm etoposide, and 2 mm cisplatin efficiently induced apoptosis in E1A-wt MEFs but not in E1A-p53À/À MEFs ( Figure 1 ). As these doses were effective at inducing p53-dependent apoptotic responses, we utilized identical doses for the arrest assays described below.
Diverse DNA-damaging agents have different abilities to activate the G1 checkpoint response in MEFs
Although the role of p53 in the G1 arrest response to gamma-irradiation has been well characterized in primary cells (Kastan et al., 1992) , the checkpoint response to other DNA-damaging agents has not. A host of DNA-damaging agents has been reported to induce p53 activity in various cell types (Nelson and Kastan, 1994) . We sought to analyse several of these agents, commonly utilized both for in vitro assays as well as in chemotherapy treatment of cancer in the clinic, in a systematic way to define their activities in G1 arrest in primary MEFs. In particular, we chose to examine doxorubicin and cisplatin, which are among the most effective and widely used chemotherapy agents. In addition, we utilized matched wild-type and p53-null MEFs to assess unambiguously the role of p53 in the cellular responses to these DNA-damaging agents. In these assays, we used FACS analysis to measure the responses of both asynchronous and synchronous cells to DNA damage. Analysis of synchronized cells allowed us to clarify specific effects of these treatments on G1 progression.
Gamma-irradiation As a standard for comparison for the various DNA-damaging agents we planned to examine, we started by treating asynchronously growing MEFs with 5 Gray (Gy) of gamma-irradiation, which induces a well-characterized arrest in both G1 and G2 (Kastan et al., 1992) . We chose to examine the effects at 18 h, a time point at which these arrest responses have been previously demonstrated. We utilized a twodimensional FACS assay in which cells are sorted for DNA content, measured by propidium iodide (PI) staining, as well as active replication, measured by bromodeoxyuridine (BrdU) incorporation. A G1 arrest response is evidenced both by an increase in cell number in G1 and by a decrease in the number of BrdUincorporating cells in the S phase in the irradiated sample compared to the untreated sample. As reported previously, we observed that wild-type cells arrest in G1 upon gamma-irradiation (Figure 2a ). In contrast, p53 mutant cells are defective in this checkpoint, with a decrease in the number of cells in G1 after treatment and with approximately the same number of cells in the S phase in untreated and gamma-irradiated samples. A useful quantitative measure of the G1 arrest response is given by the ratio of the S phase fraction after DNAdamaging agent treatment to the S phase fraction in the untreated population (Figure 5a ). This graph clearly illustrates the difference in the G1 arrest response to gamma-rays between wild-type and p53À/À cells. In addition, as seen previously, we observed a p53-independent G2 arrest, with both wild-type and p53À/À MEFs accumulating in G2 after irradiation ( Figure 2a , Table 1 ).
Doxorubicin
We next aimed to determine whether doxorubicin, another DNA-damaging agent commonly used clinically to treat a variety of cancers, acts similarly to induce p53-dependent G1 arrest and p53-independent G2 arrest responses. Doxorubicin has multiple effects, including causing DNA damage by intercalating into the DNA, inducing free radical formation, and inhibiting topoisomerase II (Stewart and Ratain, 1997) . The net result of these effects is the induction of DNA doublestrand breaks, followed by increased p53 levels and activity (Waldman et al., 1995) . We treated wild-type MEFs with 0.2 mg/ml doxorubicin and examined cells by FACS at 18 h, the time point at which G1 arrest was clearly observed upon gammairradiation. Doxorubicin induced G1 arrest in wild-type cells, as seen by the diminution of cells entering the S phase upon treatment compared to untreated cells (Figures 2b and 5a) . Although the slight decrease in the size of the G1 population upon doxorubicin treatment makes this G1 arrest somewhat unclear, it is more convincing when compared to the doxorubicin-treated p53-null cells, which showed a dramatic depletion of cells from G1, suggesting a defect in G1 arrest. In addition, when wild-type MEFs were treated with doxorubicin, cells accumulated a DNA content intermediate to 2N and 4N, indicative of an S phase arrest, although they failed to label with BrdU ( Figure 2b ). Interestingly, p53À/À cells also arrested in the S phase, but they, in contrast, incorporated BrdU. The fact that p53À/À cells attempted to replicate their DNA, and that wild-type cells did not, suggests that p53 could be involved in an S phase checkpoint that prohibits DNA replication in the presence of a DNA-damaging agent like doxorubicin. One-dimensional FACS with PI staining confirmed these findings: upon doxorubicin treatment of wild-type MEFs, we observed a late S phase arrest, with cells accumulating with a sub-4N DNA content (Figure 2c ). This accumulation also occurred in the p53-null MEFs, indicating that this S phase block is p53 independent. Finally, like gammairradiation, doxorubicin induced a G2 arrest response in both wild-type and p53À/À MEFs, as observed by a stabilization or increase in both G2 populations after treatment ( Figure 2b ). Thus, doxorubicin is similar to gamma-irradiation in inducing complex effects on MEFs -a p53-dependent G1 arrest and a p53-independent G2 arrest -but in addition it causes a p53-independent S phase arrest (Table 1) . Although the S phase arrest is p53-independent, there may be a role for p53 in preventing DNA synthesis in such conditions based on the fact that wild-type, but not p53À/À MEFs, arrested in the S phase without incorporating BrdU. The data shown here are in contrast to those reported in tumor cell lines, which failed to show any effect of doxorubicin on the S phase (Waldman et al., 1995) , and underscore the importance of characterizing such agents in primary cells.
To measure the extent of G1 arrest in doxorubicintreated cells, we synchronized MEFs in G0 by growing The ability of various DNA damaging agents to induce arrest in each phase of the cell cycle is summarized. These arrest responses are examined in wild-type and p53À/À MEFs, to determine the p53-dependence of the responses Differential effects of DNA-damaging agents in MEFs LD Attardi et al them to confluence followed by serum starvation. Serum starvation led to an efficient accumulation of MEFs in G0 (data not shown). Cells were then trypsinized and replated in the presence of 10% serum, to stimulate cell cycle re-entry. Serum stimulation facilitated robust S phase entry in wild-type and p53À/À MEFs (Figure 3) . At 6 h after serum addition, cells were either left untreated or were treated with 0.2 mg/ml doxorubicin. After an additional 18 h, cells were collected for FACS analysis. In the untreated MEFs of both genotypes, populations in the G1 and S phase were observed. Upon doxorubicin treatment, we observed a clear G1 arrest in the p53 þ / þ population, but not in the p53À/À cells, seen both as an increased percentage of cells in G1 and an absence of cells in the S phase (Figures 3 and 5b ). These data show that doxorubicin can induce a dramatic p53-dependent G1 arrest, supporting the conclusion made above in asynchronous cells.
Etoposide To examine further how generally chemotherapeutic agents induce G1 arrest in MEFs, we tested another DNA-damaging agent commonly used for chemotherapy, etoposide. Etoposide, like doxorubicin, is a topoisomerase II inhibitor that causes DNA double-strand breaks (Stewart and Ratain, 1997). Etoposide treatment has previously been shown to induce p53 protein stabilization in various cell culture systems (Nelson and Kastan, 1994) . After 18 h of etoposide treatment at a dose capable of activating p53-dependent apoptosis (see Figure 1 ), we observed a partial G1 arrest response in asynchronous wild-type MEFs by FACS, viewed as a slight decrease in the population in the S phase (Figures 4 and 5a) . That this is a p53-dependent G1 arrest is bolstered by the finding that p53-null cells have no block leaving G1 and no depletion of cells entering the S phase. The extent of this arrest was, however, never as potent as that induced by doxorubicin, likely because this dose of etoposide is somewhat less effective at inducing p53 activity ( Figure 6 ). Instead, the most pronounced effect when wild-type cells were treated with etoposide was that cells accumulated at the 4N stage, either late S or G2 (Figure 4) . Like wild-type MEFs, p53À/À MEFs also accumulated in late S/G2 after etoposide treatment. Thus, although this dose of etoposide can induce a partial p53-dependent G1 arrest response in asynchronous cells, the p53-independent G2 arrest is the most pronounced response (Table 1) .
To clarify further the ability of etoposide to activate G1 arrest, we synchronized cells as described above, and treated them with 2 mm etoposide. There was again a partial G1 arrest response in wild-type MEFs, with some accumulation of cells in G1 and inhibition of entry of cells into the S phase (Figures 3 and 5b) . This G1 arrest response to etoposide is p53-dependent as there is no effect of etoposide on the cell cycle progression of p53À/À MEFs. To determine if the partial G1 arrest response observed with etoposide could be enhanced, we tested a significantly higher dose that induces a largely p53-independent apoptosis in hyperproliferative MEFs (data not shown). Upon treatment with 75 mm etoposide, a more effective G1 arrest was observed (Figures 3 and  5b) , although it was still not quite as strong as the arrest induced by doxorubicin. Thus, etoposide shares with doxorubicin the ability to inhibit topoisomerase II, activate p53, and inhibit G1 progression (Table 1) . Interestingly, however, unlike with doxorubicin, a much larger dose is required to induce p53-dependent G1 arrest in MEFs than to activate p53-dependent apoptosis in E1A-MEFs.
Cisplatin Next, we tested the widely used chemotherapeutic agent cisplatin for its ability to induce G1 arrest, as a representative DNA-damaging agent acting via a different mechanism from the other agents we examined. Cisplatin damages DNA by forming intrastrand and , 1997) , and it has been reported to activate p53 (Zamble et al., 1998) . We observed no obvious G1 arrest response in either wildtype or p53À/À asynchronous MEFs upon cisplatin treatment for 18 h (Figures 4 and 5a) . Instead, we observed that wild-type cells accumulated in the S phase after cisplatin treatment. Similarly, in p53-null cells, cisplatin treatment failed to induce G1 arrest and induced S phase arrest. Analysis of synchronized wildtype cells confirmed the inability of cisplatin to activate the G1 arrest checkpoint response, in contrast to the other agents tested (Figures 3 and 5b , Table 1 ). Moreover, 10-fold higher doses of cisplatin still failed to induce a G1 arrest response (data not shown). These findings clearly indicate that being a DNA-damaging agent that can activate p53 does not necessarily mean that such an agent will induce p53-mediated arrest. Interestingly, unlike the other DNA-damaging agents, cisplatin did not clearly induce a strong G2 arrest response, which would be viewed as an increase in G2 cell number, presumably because of the drastic block of cells in the S phase that prohibits transit of S phase cells into G2.
UVC An additional DNA-damaging agent that activates p53 besides the chemotherapeutics described above is UVC light (Appella and Anderson, 2001 ). Gamma-rays as well as agents like doxorubicin and etoposide, induce DNA double-strand breaks, which are sensed at least in part by the ATM protein kinase (Zhou and Elledge, 2000; Tang et al., 2002) . ATM induces p53 stabilization both directly, through phosphorylation of p53, and indirectly, through activation of the Chk2 kinase, which phosphorylates p53 (Zhou and Elledge, . In contrast, UVC light damages DNA by inducing the formation of pyrimidine dimers and six to four photoproducts (Appella and Anderson, 2001) , and activates p53 through a different route, likely involving ATR. We examined the ability of UVC to induce a p53-dependent G1 arrest as a representative agent acting through a distinct, non-ATM-dependent mechanism. We synchronized wild-type and p53-null MEFs, released them into the cell cycle and treated them with 20 J/m 2 of UVC light, a dose known to induce the expression of p53 target genes such as p21 (see Figure 6 ). By FACS, we observed similar profiles in both wild-type and p53-null MEFs: UVC light induced an increase in the number of cells in G1 and a drastic reduction in the number of cells in the S phase (Figures 3 and 5b) . UVC treatment also induced an accumulation of MEFs of both genotypes in G2. These data indicate that UVC light activates p53-independent G1 and G2 arrest responses (Table 1) , and again reiterate the point that not all DNA-damaging agents induce p53-dependent arrest responses in MEFs.
Different DNA-damaging agents activate the p21 target gene in a p53-dependent manner
The p21 cyclin-dependent kinase (CDKs) inhibitor is an important component of the p53 G1 arrest response to gamma-irradiation (Brugarolas et al., 1995; Deng et al., 1995; Waldman et al., 1995) . Upon gamma-ray treatment, p53 levels in the cell rise and p53 directly activates the p21 promoter, resulting in increased p21 levels (ElDeiry et al., 1993) . Induced p21 then binds to CDKs and inhibits their activity, causing cells to arrest in G1 (Pines, 1994) . To determine the basis of the differential ability of the DNA-damaging agents examined to induce G1 arrest, we analysed their ability to activate p21. We treated wild-type and p53À/À MEFs with doxorubicin, etoposide, cisplatin, or UVC at the doses utilized for the apoptosis and arrest assays shown earlier. We found that all these DNA-damaging agents could induce p21 message efficiently in wild type, but not p53À/À MEFs, indicating that all of these agents can activate p53 and cause induction of this crucial arrest target gene ( Figure 6 ). Although p21 was induced by all agents, there was some variability in the levels observed, which could account for some of the differences in effects induced by the various agents. For example, the lower levels of p21 induced by 2 mm etoposide may account for its weaker G1 arrest activity compared to doxorubicin. In contrast, the failure of cisplatin to induce G1 arrest cannot be explained by its inability to cause p21 induction. The levels of p21 induced by cisplatin are higher than those induced by etoposide, where a partial G1 arrest response is seen, yet there is no apparent G1 arrest in cisplatin-treated MEFs. This finding indicates that the presence of active p53 and consequent p21 induction are not sufficient to cause G1 arrest in all cases. Together, these observations suggest that the model in which DNA damage activates p53, which in turn leads to p21 induction and G1 arrest, is an oversimplification. Furthermore, although UVC activates p21 expression in a p53-dependent manner, it still arrests cells in G1 in a p53-independent manner, suggesting that it causes a p21-independent response. Clearly, the exact mechanism of the cell cycle arrest depends on the DNA-damaging agent tested and might involve the activation of genes thus far unknown.
UVC induces apoptosis in nonhyperproliferative MEFs
As UVC could induce a p53-independent G1 arrest response, we tested whether it could also induce p53-independent apoptosis in MEFs. We started by treating wild-type and p53À/À MEFs with 20 J/m 2 UVC, and surprisingly, unlike chemotherapeutic agents (Lowe et al., 1993) , we found that UVC light could induce cell death in non-E1A-expressing MEFs (Figure 7 ). This cell death had both p53-dependent and p53-independent components; apoptosis was more rapid in wild-type MEFs than in p53-null MEFs, but p53À/À cells were eventually susceptible to apoptosis. The different Alternatively, pyrimidine dimers may be repaired less efficiently than double-strand breaks, leading to a more sustained damage signal that triggers apoptosis.
Discussion
The p53 tumor suppressor is a key player in the DNA damage response, integrating DNA damage signals and inducing either G1 arrest or apoptosis, depending on the exact cellular context (Bargonetti and Manfredi, 2002) . Here, we characterized the response of wild-type and p53À/À MEFs to several widely used chemotherapeutics and UVC in cell cycle arrest. While analysis of cell cycle responses to DNA damage has been performed in a variety of tumor cells previously, it has not been thoroughly examined in primary cells, which is important for understanding how normal, untransformed cells respond to these diverse agents. Gammairradiation of MEFs results in a well-characterized p53-dependent G1 arrest response, which we have used here as a standard for comparison in investigating other DNA-damaging agents, including doxorubicin, etoposide, cisplatin, and UVC, whose actions have not been extensively examined in primary fibroblasts. We chose these agents because they represent agents that induce DNA damage through different mechanisms and activate p53 through different pathways, and because several of them are important clinically for the treatment of cancer. We found that these diverse DNA-damaging agents have surprisingly different activities in primary fibroblasts. Interestingly, we found that although all these agents can activate p53 apoptotic and transcriptional activity, they do not all have equivalent activities in cell cycle arrest. Doxorubicin, a DNA double-strand break inducer, induced a potent p53-dependent G1 arrest response that is particularly clear in synchronized cells. The high efficacy of doxorubicin may be because of its ability to induce DNA damage in multiple ways, leading to a strong DNA damage signal. Etoposide, another DNA double-strand break inducer, in contrast, had only partial p53-dependent G1 arrest activity at doses active for causing p53-dependent apoptosis in hyperproliferative MEFs. Interestingly, however, higher doses of etoposide could efficiently induce p53-dependent G1 arrest. This finding suggests that there are different requirements for p53 activation by etoposide in arresting MEFs compared to apoptotic E1A-MEFs. As for cisplatin, which causes DNA damage by inducing DNA crosslinks, it did not induce an arrest in G1. Curiously, p53 was activated by cisplatin treatment of MEFs, as judged by the induction of p21 in wild-type but not p53À/À MEFs. Thus, although p21 was induced by p53 in cisplatin-treated cells, there was no arrest, suggesting that neither p53 activation nor p21 transcriptional induction is sufficient to induce an arrest response. The explanation for this finding is unclear, but one possibility is that there may be an additional signal conferred by double-strand breaks that is essential for the p53 arrest response. Finally, we examined the effects of UVC, which damages DNA through the induction of pyrimidine dimers, and found that UVC induced a p53-independent G1 arrest response. Interestingly, we saw that p53 is activated, as p21 was induced in a p53-dependent manner by UVC, but the observed G1 arrest was not dependent on that induction of p53. These data suggest further that p21 induction is not responsible for the arrest activated by UVC. The mechanism of this p53-independent arrest by UVC is unknown, but it could occur via an indirect mechanism such as global transcriptional inhibition of key cell cycle regulators like cyclin E (Chang et al., 1999) . Taken together, these studies indicate that the idea that activation of p53 by DNA damage in MEFs leads to G1 arrest is an oversimplification. Multiple signals may be needed to activate p53 to a functional form for arrest, and this is only achieved by certain DNA-damaging agents.
In addition, we examined the ability of these different agents to induce cell cycle responses in other phases of the cell cycle, and the effects we observed are consistent with the known mechanism of action of these agents. For example, doxorubicin and etoposide, both doublestrand break inducers and topoisomerase II inhibitors, activated G2 arrest responses, consistent with their abilities to inhibit topoisomerase II. Cisplatin caused an S phase arrest, which fits well with our knowledge that cisplatin induces DNA crosslinks, effectively inhibiting replication in the process. In addition, the analysis of doxorubicin-treated cells indicated a p53-independent S phase arrest response. This is possibly because of the ability of doxorubicin to intercalate into DNA and disrupt its structure, thus impeding DNA replication. Interestingly, we observed that wild-type MEFs treated with doxorubicin arrested in the S phase and failed to incorporate BrdU, while p53À/À MEFs arrested in the S phase but continued to incorporate BrdU. This finding suggests that p53 may play a role in inhibiting DNA synthesis in a situation in which the cell is stalled in the S phase, indicating a potential role for p53 in monitoring an S phase checkpoint.
While MEFs undergo various cell cycle arrest responses after DNA damage, E1A-expessing MEFs undergo p53-mediated apoptosis upon DNA damage. Here, doxorubicin, etoposide, and cisplatin were all able to induce apoptosis in E1A-expessing MEFs effectively. Interestingly, although cisplatin could activate p53 to induce apoptosis in E1A-MEFs, it could not activate p53 to induce arrest in MEFs. This finding suggests that cisplatin can selectively activate p53 to perform one of its functions, that of apoptosis in the context of an oncogenic signal, but not that of G1 arrest. This observation suggests that there is some difference in p53 activity depending on both cell type and method of activation; perhaps, E1A provides a signal to p53 that is missing in cisplatin-treated MEFs. In addition, UVC treatment induced apoptosis in MEFs without requiring a hyperproliferative signal, suggesting a fundamentally different mechanism of activating apoptosis from the other agents. This could reflect either a different pathway activated by UVC, or a greater inability to repair UVC lesions, which ultimately leads to cell death.
The differential activities of various DNA-damaging agents may be accounted for by the signal transduction pathways activated by diverse agents and by their differential abilities to induce p53 modifications. Indeed, there is evidence from studies of a variety of agents that they cause different post-translational modifications of p53. For example, UVC causes phosphorylation of p53 at residue 389, but gamma-rays do not (Kapoor and Lozano, 1998; Lu et al., 1998) . Perhaps, these differentially modified forms of p53 have different activities. The ability of a certain form of p53 to activate specific genes may account for why one DNA-damaging agent activates a given response and not others. These findings clearly indicate the complexity of the cellular response to DNA damage, in that the exact response of the cell depends not only on the cell type but also on the specific DNA damage trigger.
Materials and methods
MEF preparation and analysis
MEFs were prepared, and FACS analysis was performed as described (Brugarolas et al., 1995) . Experiments were performed with early passage MEFs (prior to passage 6). Doxorubicin, etoposide, and cisplatin were used at indicated concentrations (Sigma). Gamma-irradiation was performed using a 137 Cs source, and UVC light was administered using a Stratalinker (Stratagene). After FACS analysis (Brugarolas et al., 1995) , fractions of cells in each phase of the cell cycle were quantitated using CellQuest software (Becton Dickinson). To synchronize cells in G0 for cell cycle arrest assays, MEFs were grown to confluence and then placed into media with 0.1% fetal calf serum for 4 days before performing the assays. For apoptosis assays, retroviral infection of MEFs with E1A and assessment of apoptosis by trypan blue exclusion were performed as described (Attardi et al., 2000) .
Northern blot analysis
Northern blot analysis was performed using standard methods. The p21 and GAPDH probes have been described (Attardi et al., 2000) .
